Gefitinib Usage and Outcomes in Routine Treatment

First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation

NCT00344773 ·Status: COMPLETED ·Phase: PHASE2

Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT00536107 ·Status: TERMINATED ·Phase: PHASE4

Gefitinib 500mg Versus 250mg in Patients With NSCLC With Stable Disease After a Month Treatment of Gefitinib 250mg

NCT01017679 ·Status: COMPLETED ·Phase: PHASE2

the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer)

NCT03264794 ·Status: UNKNOWN ·Phase: PHASE4

Selumetinib in Combination With Gefitinib in NSCLC Patients

NCT02025114 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients

NCT04390984 ·Status: UNKNOWN ·Phase: PHASE1

Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC

NCT04425187 ·Status: UNKNOWN ·Phase: PHASE2

Second-Line Irinotecan or Gefitinib in Docetaxel Pretreated NSCLC

NCT00319800 ·Status: UNKNOWN ·Phase: PHASE2

Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations

NCT01024413 ·Status: COMPLETED ·Phase: PHASE3

First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker

NCT00455936 ·Status: COMPLETED ·Phase: PHASE3

Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC

NCT06863506 ·Status: RECRUITING ·Phase: PHASE2

Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC

NCT01203917 ·Status: COMPLETED ·Phase: PHASE4

Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc

NCT01955421 ·Status: UNKNOWN ·Phase: PHASE2

A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)

NCT01480141 ·Status: WITHDRAWN ·Phase: PHASE2

Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients

NCT01040780 ·Status: COMPLETED ·Phase: PHASE3

Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib

NCT00522145 ·Status: COMPLETED ·Phase: PHASE2

A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment

NCT01994057 ·Status: RECRUITING

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).

NCT02088112 ·Status: COMPLETED ·Phase: PHASE1

Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer

NCT03647592 ·Status: RECRUITING

A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.

NCT01250119 ·Status: COMPLETED ·Phase: PHASE2

Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC

NCT02299765 ·Status: TERMINATED ·Phase: PHASE4

An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer (GERTAC)

NCT01790217 ·Status: COMPLETED

Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00411047 ·Status: COMPLETED ·Phase: PHASE2

To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma

NCT03656393 ·Status: UNKNOWN ·Phase: PHASE3

PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery

NCT02804776 ·Status: COMPLETED ·Phase: PHASE2